Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | TP53 | P04637 | 2/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.84 |
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.53 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 2/20 | 0.52 |
| ▸ | HINT1 | P49773 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120550 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL3478703 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL1120556 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL278443 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL313898 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13924747 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13296259 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL3427712 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL6363586 | 0.95 | LMNA (0.76) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL17198377 | 0.93 | ALDH1A1 (0.73) | LMNAALDH1A1TP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943251-B8 | A1 ADENOSINE RECEPTOR AGONISTS | GILEAD PALO ALTO INC (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1943251-B1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-1537135-B1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090137520-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ELZEIN ELFATIH | 2009-05-28 | — | — | US | disclosed |
| US-7488720-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1943251-A2 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007047401-A2 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070087994-A1 | treating tachycardia and atrial flutter, angina, and myocardial infarction; N-({9-[(4S ,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(cyclopentylamino)purin-2-yl}methyl)carbamoylmethylsulfonic acid | CV THERAPEUTICS, INC. | 2007-04-19 | — | — | US | disclosed |
| US-6914053-B2 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1537135-A2 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040121978-A1 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004022573-A2 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137520-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ADORA1, ADORA2A, ADORA3 | LMNA 2001/4885ALDH1A1 129/4885TP53 4125/4885 |
| US-20040121978-A1 | Adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | LMNA 2972/4885ALDH1A1 811/4885TP53 1698/4885 |
| US-20070087994-A1 | treating tachycardia and atrial flutter, angina, and myocardial infarction; N-({9-[(4S ,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(cyclopentylamino)purin-2-yl}methyl)carbamoylmethylsulfonic acid | FFAR1, ADORA3, ADORA1 | LMNA 3102/4885ALDH1A1 472/4885TP53 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.